MedTrace Logo

Edoxaban in Peripheral Arterial Disease

NCT01802775 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 203

Last updated 2019-02-26

Study results available
· View outcomes & findings →

Summary

This study is a randomized, open-label, blinded endpoint, parallel-group, active-control, multi-center, proof-of-concept study in subjects with Peripheral Arterial Disease (PAD), designed to assess the safety and potential efficacy of adding edoxaban to aspirin following femoropopliteal endovascular intervention, with or without stent placement, relative to current treatment practice with clopidogrel and aspirin.

Conditions

  • Peripheral Arterial Disease

Interventions

DRUG

edoxaban

DRUG

Clopidogrel

75mg tablet

DRUG

Aspirin

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Leader · Daiichi Sankyo

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-06
Primary Completion
2014-12-03
Completion
2014-12-03

Countries

  • United States
  • Austria
  • Belgium
  • Germany
  • Israel
  • Netherlands
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01802775 on ClinicalTrials.gov